Phesgo 1200mg/600mg Injection

Phesgo 1200mg/600mg Injection is a targeted therapy containing pertuzumab and trastuzumab. It is indicated for treatment of human epidermal growth factor receptor 2 positive breast cancer that has metastasised to other parts of the body, or breast cancer that has recurred following prior treatment. The injection may also be administered before or after surgery in patients with non-metastasised breast cancer. Cancer develops when cells undergo uncontrolled abnormal growth. Prior to receiving Phesgo 1200mg/600mg Injection, inform your physician if you have cardiac conditions, have undergone radiotherapy, or have allergic conditions. This medication is not recommended in patients under 18 years of age. In patients with early-stage HER2-positive breast cancer, addition of pertuzumab or trastuzumab to standard chemotherapy can reduce recurrence risk and improve disease-free survival.

Phesgo 1200mg 600mg Injection is used to manage the following conditions: Early breast cancer Metastatic breast cancer

Phesgo (pertuzumab and trastuzumab) 1200mg/600mg injection is a fixed-dose combination therapy used for HER2-positive breast cancer, offering the therapeutic benefits of both monoclonal antibodies in a convenient subcutaneous formulation. Pertuzumab prevents HER2 receptor dimerization, while trastuzumab blocks HER2 signalling and triggers immune-mediated tumour cell destruction, collectively inhibiting cancer cell growth and proliferation. By targeting HER2-positive cells, Phesgo reduces tumour progression, improves survival rates, and enhances treatment convenience compared to intravenous administration.

Phesgo 1200mg/600mg Injection is administered subcutaneously, not intravenously. The initial loading dose of 1,200 mg pertuzumab and 600 mg trastuzumab is given over approximately 8 minutes, followed every three weeks by a maintenance dose of 600 mg pertuzumab and 600 mg trastuzumab administered over approximately 5 minutes. Injections should alternate between the left and right thighs, ensuring each new injection is at least 2.5 cm away from the previous site and avoiding areas that are red, bruised, tender, or hard. Do not split the dose between multiple syringes or injection sites. After administering the loading dose, observe the patient for 30 minutes; for maintenance doses, a 15-minute observation period is recommended to monitor for injection-related reactions. If a serious hypersensitivity reaction occurs, discontinue the injection immediately and permanently.

Side effects are unwanted symptoms caused by medicines. Even though all medicines cause side effects, not everyone gets them. The Phesgo Injection side effects are: Common side effects of Phesgo 1200mg/600mg Injection are: Alopecia (hair loss) Nausea Diarrhea Anemia Asthenia (weakness) Fatigue Stomatitis (inflammation of the mouth) Myalgia (muscle pain) Arthralgia (joint pain) Constipation Neutropenia (low white blood cell count) Vomiting Radiation skin injury Dysgeusia (altered taste) Headache Decreased appetite Insomnia Peripheral sensory neuropathy Rash Dry skin Mucosal inflammation Injection site reactions (e.g., pain, redness) Cough Serious Side Effects: Febrile neutropenia (fever with low white blood cell count) Neutropenic sepsis (a severe infection due to low white blood cell count) Decreased ejection fraction (a measure of heart function) Cardiac failure Pneumonitis/pulmonary fibrosis (lung inflammation or scarring) Hypersensitivity reactions, including anaphylaxis Severe injection-related reactions

If you have prescribed Phesgo 1200mg 600mg Injection, or any other medication, it is important to carefully read and understand the warnings and precautions associated with the medication. Patients should be monitored for signs of an allergic reaction, such as rash, itching, or swelling, and should seek immediate medical attention if these symptoms occur. It should be used with caution in patients with severe renal impairment. Talk to the physician if you have heart problems, have had radiotherapy, or have allergic conditions. Use effective birth control during the treatment and at least seven months after the last dose. Always maintain a healthy and balanced diet to support your overall health and well-being.